Elite Pharmaceuticals Begins Human Abuse Liability Studies for ELI-200
09 juin 2014 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 9, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced dosing of the first subject in the treatment phase for a human...
Elite Pharmaceuticals Announces Results of 2014 Annual Meeting of Shareholders
23 mai 2014 11h08 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 23, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) today announced the voting results of matters considered during the...
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Third Opioid Abuse Deterrent Product
19 mai 2014 08h15 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 19, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in...
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
22 avr. 2014 07h41 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 22, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled...
Elite Pharmaceuticals, Inc. Secures Funding Commitment of Up to $40 Million From Lincoln Park Capital Fund, LLC
14 avr. 2014 07h30 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 14, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today that it has entered into a common stock purchase agreement with...
Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
27 mars 2014 12h15 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 27, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it has created the position of Vice President, Quality...
Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
24 mars 2014 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 24, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being...
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
10 mars 2014 07h46 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding...
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
05 mars 2014 07h30 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated...
Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
18 févr. 2014 07h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study...